tbuckley/cabot-search huggingface dataset:
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Authors: Elisabeth Hessmann, Steven A Johnsen, Jens T Siveke, Volker Ellenrieder
Journal: Gut (2016)

Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive malignancies with a 5-year survival rate of &lt;7%. Due to growing incidence, late diagnosis and insufficient treatment options, PDAC is predicted to soon become one of the leading causes of cancer-related death. Although intensified cytostatic combinations, particularly gemcitabine plus nab-paclitaxel and the folinic acid, fluorouracil, irinotecan, oxaliplatin (FOLFIRINOX) protocol, provide some improvement in efficacy and survival compared with gemcitabine alone, a breakthrough in the treatment of metastatic pancreatic cancer remains out of sight. Nevertheless, recent translational research activities propose that either modulation of the immune response or pharmacological targeting of epigenetic modifications alone, or in combination with chemotherapy, might open highly powerful therapeutic avenues in GI cancer entities, including pancreatic cancer. Deregulation of key epigenetic factors and chromatin-modifying proteins, particularly those responsible for the addition, removal or recognition of post-translational histone modifications, are frequently found in human pancreatic cancer and hence constitute particularly exciting treatment opportunities. This review summarises both current clinical trial activities and discovery programmes initiated throughout the biopharma landscape, and critically discusses the chances, hurdles and limitations of epigenetic-based therapy in future PDAC treatment.
First DMD Drug Gains Approval
Authors: Rebecca Voelker
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterization of Extramedullary Acute Myeloid Leukemia – Results of the AML96 Trial
Authors: Friedrich Stölzel, Christoph Röllig, Michael Kramer, Brigitte Mohr, Uta Oelschlägel, Jörgen Radke, Christian Thiede, Martin Bornhaeuser, Gerhard Ehninger, Markus Schaich
Journal: Blood (2010)
NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia
Authors: Krzysztof Giannopoulos, Malgorzata Zajac, Anna Dolnik, Matthias Schunn, Stephany Correa, Eliza Glodkowska-Mrowka, Reddy Chakkarappan Sundaram, Olga Jankowska-Lecka, Richard Schlenk, Konstanze Dohner, Lars Bullinger
Journal: Blood (2014)
Arguing (About) the Value of Cancer Care
Authors: Ivo Abraham, Ali McBride, Karen MacDonald
Journal: Journal of the National Comprehensive Cancer Network (2016)

The debate about the escalating cost of caring for patients with cancer may soon derail into an argument (as in, dispute) that will not help those providing care, those developing treatments, and those paying for care.In the process, the voice of patients-as co-decision-maker, recipient, and copayer of this care-may grow even fainter.Pointing out what others (presumably) do wrong, (presumably) fail to do, or (presumably) should do differently to stem the rising costs of cancer treatment is easy.Building a collective argument (as in, case) that balances the interests and concerns of all stakeholders-and does so in a clinically responsible, economically accountable, and patient-centered manner-is much harder.Some hard questions must be answered by all stakeholders.These are our thoughts on them.
Improved Therapeutic Index of Carboplatin Plus Cyclophosphamide Versus Cisplatin Plus Cyclophosphamide
Authors: David S. Alberts, Stephanie Green, Edward V. Hannigan, Robert O'Toole, Donna Stock-Novack, Patricia Anderson, Earl A. Surwit, Vinay K. Malvlya, William A. Nahhas, Christopher J. Jolles
Journal: Journal of Clinical Oncology (1992)

There was an error in Table 9 of the report "Improved Therapeutic Index of Carboplatin Plus Cyclophosphamide Versus Cisplatin Plus Cyclophosphamide: Final Report by the Southwest Oncology Group of a Phase III Randomized Trial in Stages III and IV Ovarian Cancer" by Alberts et al (J Clin Oncol 10:706–717, 1992). The dosage of cisplatin given in the table for the report by Kato et al (cited as reference 21) should have been 50 mg/m 2 . The table is reprinted here correctly in its entirety: Please see the PDF for Table.
CBIO-21INFLUENCES OF BLOOD BRAIN BARRIER (BBB) BASEMENT MEMBRANE ECM MOLECULES ON HUMAN BRAIN VASCULAR PERICYTES
Authors: Zaynah Maherally, Amelia Willcock, Friederike Quack, Helen Fillmore, Geoffrey Pilkington
Journal: Neuro-Oncology (2015)

BACKGROUND: Pericytes are specialised cells found within the blood brain barrier (BBB) ensheathed by a basement membrane (BM) containing numerous extracellular matrix (ECM) proteins which regulate vessel stabilisation and barrier formation. Knowledge on ECM influence on pericyte behaviour is limited. This study aimed to determine the effects of BM-ECM components on pericyte proliferation, adhesion, motility and cell-to-cell contact. METHODS: Human brain vascular pericytes (HBVP) were used. Cell seeding number was optimised and cells were plated on different human-derived, previously optimised, ECM molecules including Fibronectin (5 µg/ml), Laminin (75 µg/ml), Collagen IV (10 µg/ml), Agrin (1 µg/ml) and Perlecan (10 µg/ml) and assessed for proliferation and both quantitative and qualitative adhesion. Motility assays were performed using live cell (time-lapse) imaging. Resistance values between pericytes were collated using an Electric Cell-Substrate Impedance Sensing (ECIS) system. Trans-Endothelial Electrical Resistance (TEER) changes when pericytes were seeded onto human endothelial cells under the different ECM culture conditions were also analysed by voltometer and ECIS. RESULTS: Cells adhered best when seeded on Perlecan and least well on Agrin (p < 0.05). Motility assays showed that pericytes travelled the longest distance and fastest on Agrin and least on Perlecan (p < 0.05). Higher resistance values were reached when cells were plated on Perlecan (∼400 Ω/cm2) and least on Agrin (∼300 Ω/cm2). A tighter barrier was noted when pericytes were co-cultured with endothelial cells (1200 Ω/cm2) compared to when pericytes were added to endothelial cell monolayers (1000 Ω/cm2). CONCLUSIONS: Results demonstrate that different BBB basement molecules have varied effects on TEER values, one indicator of BBB function. Findings also suggest that Agrin may function to recruit pericytes by migration while Perlecan may function to serve as an anchor. This study highlights the importance of BM-ECM molecules and suggests a concentration dependant role of the perlecan/agrin axis in BBB establishment and function.
Gene Expression Profiles Are Best Suited To Assess Present Though Not Future Clinical Aggressiveness in Follicular Lymphoma.
Authors: Annuska M. Glas, Marie Jose Kersten, Leonie Delahaye, Robby E. Kibbelaar, Joannes H.J.M. Van Krieken, Philip M. Kluin, Laura J. van ‘t Veer, Daphne de Jong
Journal: Blood (2004)
Adipocyte Ceramides Regulate Subcutaneous Adipose Browning, Inflammation, and Metabolism
Authors: Bhagirath Chaurasia, Vincent Andre Kaddai, Graeme Iain Lancaster, Darren C. Henstridge, Sandhya Sriram, Dwight Lark Anolin Galam, Venkatesh Gopalan, K.N. Bhanu Prakash, S. Sendhil Velan, Sarada Bulchand, Teh Jing Tsong, Mei Wang, Monowarul Mobin Siddique, Guan Yuguang, Kristmundur Sigmundsson, Natalie A. Mellet, Jacquelyn M. Weir, Peter J. Meikle, M. Shabeer Bin M. Yassin, Asim Shabbir, James A. Shayman, Yoshio Hirabayashi, Sue-Anne Toh Ee Shiow, Shigeki Sugii, Scott A. Summers
Journal: Cell Metabolism (2016)
Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)
Authors: Peter M. Voorhees, Brendan Weiss, Saad Usmani, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Sagar Lonial
Journal: Blood (2015)
Validation of Mantle Cell International Prognostic Index (MIPI) in Mantle Cell Lymphoma (MCL) in a Retrospective Single Institution Series
Authors: Annalisa Chiappella, Barbara Botto, Filippo Marmont, Ernesta Audisio, Ileana Baldi, Giulia Benevolo, Carola Boccomini, Stefano D’Ardia, Chiara Frairia, Roberto Freilone, Lorella Orsucci, Patrizia Pregno, Umberto Vitolo
Journal: Blood (2008)
ALLOMETRIC SCALING OF VO <sub>2max</sub> : A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: L Lolli, AM Batterham, KL Weston, G Atkinson
Journal: British Journal of Sports Medicine (2016)

We aimed to provide the first quantitative synthesis of derived static allometric coefficients ( b ) used for scaling maximal oxygen uptake (VO 2max ) to whole-body mass and fat-free mass in human samples. Eight electronic databases were searched for relevant peer-reviewed articles. Inclusion criteria comprised human cardiorespiratory fitness data; cross-sectional study designs; an empirical derivation of the exponent; reported precision statistics; and reported information regarding participant sex, age and sports background, VO 2max protocol, body composition protocol and line-fitting methods. Thirty-seven studies, involving 7,851 participants, met the eligibility criteria and were dichotomized into two main domains relevant to whole-body mass (n=28) and fat-free mass (n=16), respectively. The pooled allometric exponent (95% CL) was found to be 0.71 (0.65 to 0.77) for body mass and 0.91 (0.83 to 0.98) for fat-free mass. The among-studies heterogeneity was substantial for both whole-body mass and fat-free mass (τ =±0.15). Participant sex explained 33% of the between-study variability in the whole body mass exponent, but only 5% of the variability in the fat-free mass exponent. While the body mass exponent was substantially lower in women ( b =0.52; 95% CL: 0.41 to 0.64) than for men ( b =0.77; 95% CL: 0.71 to 0.83), the fat-free mass exponent was similar for both sexes. None of the identified moderator variables was statistically significant. The body mass exponent estimate encompassed both ⅔- and ¾-power laws. Conversely, the fat-free mass exponent was substantially larger and more generalisable due to the heterogeneity of body composition in human samples. We conclude that the scaling of VO 2max in humans is consistent with the allometric cascade model, with an estimated pooled exponent that precludes ⅔- and ¾-power scaling.
Moving From Disability to Possibility
Authors: Kurt R. Herzer
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Allogeneic Transplant In Children with Severe Aplastic Anemia – Excellent Outcomes with the Use of a Fludarabine Based Conditioning Regimen
Authors: Biju George, Vikram Mathews, Auro Viswabandhya, Aby Abraham, Lakshmi M Kavitha, Mammen Chandy, Alok Srivastava
Journal: Blood (2010)
Analysis of CD20-Mediated Signals in Refractory Diffuse Large B-Cell Lymphoma Cells.
Authors: Tsuyoshi Nakamaki, Kunihiko Fukuchi, Hidetoshi Nakashima, Hirotsugu Ariizumi, Takashi Maeda, Bungo Saito, Kouji Yanagisawa, Shigeru Tomoyasu
Journal: Blood (2012)
Doubts About Therapy for Neurological Diseases With Antisense Oligonucleotides
Authors: Satyakam Bhagavati
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Unusual Presentations of Lymphoma
Authors: Raymond S. McDermott, Michael M. Maher, Kieron Dunleavy, Conor J. O’Keane, John P. Stack, Desmond P. Carney
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.7.1943 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11919256 Unusual Presentations of Lymphoma Case 2. Non-Hodgkin's Lymphoma Presenting as Liver Disease Raymond S. McDermottxRaymond S. McDermottSearch for articles by this author , Michael M. MaherxMichael M. MaherSearch for articles by this author , Kieron DunleavyxKieron DunleavySearch for articles by this author , Conor J. O’KeanexConor J. O’KeaneSearch for articles by this author , John P. StackxJohn P. StackSearch for articles by this author , Desmond P. CarneyxDesmond P. CarneySearch for articles by this author Show More Mater Misericordiae Hospital, Eccles Street, Dublin 7, Ireland https://doi.org/10.1200/JCO.2002.20.7.1943 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Trends in Prostate Cancer Screening Following Changes Made by the US Preventive Services Task Force
Authors: Pauline Filippou, Raj S. Pruthi
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
JAK2 Mutation in Granulocytes and Platelets and X-Chromosome Gene-Based Clonal Analysis in Chronic Myeloproliferative Disorders.
Authors: Kohtaro Toyama, Norifumi Tsukamoto, Irisawa Hiroyuki, Akihiko Yokohama, Takayuki Saitoh, Hiroshi Handa, Takafumi Matsushima, Hirokazu Murakami, Shuichi Miyawaki, Yoshihisa Nojima, Masamitsu Karasawa
Journal: Blood (2006)
MNGO-20SOMATOSTATIN RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR PROGRESSIVE MENINGIOMA
Authors: Katharina Seystahl, Veit Stoecklein, Ulrich Schüller, Elisabeth Rushing, Guillaume Nicolas, Niklaus Schäfer, Harun Ilhan, Athina Pangalu, Michael Weller, Jörg-Christian Tonn, Michael Sommerauer, Nathalie Jansen
Journal: Neuro-Oncology (2015)

BACKGROUND: There is no standard of care beyond surgery and radiotherapy for patients with progressive meningioma. Somatostatin receptors have been proposed as therapeutic targets. However, systemic administration of somatostatin analogs has shown only limited efficacy. Somatostatin receptor-targeted radionuclide therapy represents a novel treatment option for progressive meningioma. METHODS: In a retrospective analysis, we assessed safety and efficacy of somatostatin receptor-targeted radionuclide therapy (90Y-DOTATOC (n = 3) or 177Lu-DOTATATE (n = 16) or both (n = 1)) in 20 patients with progressive, treatment-refractory meningiomas (histological grading: 5 WHO grade I, 7 WHO grade II, 8 WHO grade III meningiomas). Changes in the growth rate before and after therapy were assessed by volumetric analysis where applicable. RESULTS: Somatostatin receptor radionuclide treatment was well tolerated. A median of 3 treatment cycles were given (median administered dose per cycle 7400 MBq). Response to treatment was moderate with disease stabilization in 10 of 20 patients for a median time of 17 months. Median progression-free survival (PFS) for all patients was 5.4 months, 32.2 months for grade I, 7.6 months for grade II and 2.1 months for grade III meningiomas. PFS correlated inversely with tumor grade. Median overall survival from start of intervention was not reached at a medium follow-up time of 20 months. Volumetric measurement showed a reduction of more than 25% of growth rate after therapy in 4 of 8 patients analyzed. Correlation between intensity of somatostatin receptor expression of single meningioma lesions via 68Ga-DOTATOC/-TATE-PET/CT or via immunohistochemistry and outcome was investigated. CONCLUSION: Somatostatin receptor-targeted radionuclide treatment is a safe therapy option in patients with progressive meningioma and is effective in a subset of patients with WHO grade I and grade II meningioma requiring systemic therapy, but might have limited efficacy in patients with WHO grade III meningioma.
Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides
Authors: Erden Atilla, Pinar Ataca, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Bengu Nisa Akay, Hatice Sanli, Pervin Topcuoglu, Muhit Ozcan, Gunhan Gurman, Osman Ilhan
Journal: Blood (2015)
Indoleamine 2,3-Dioxygenase Is Expressed and Functionally Active in Human Dermal Dendritic Cells, but Not in Epidermal Langherans Cells.
Authors: Antonio Curti, Sara Trabanelli, Darina Ocadlikova, Sergio Rutella, Raimondo De Cristofaro, Michele Baccarani, Roberto M Lemoli
Journal: Blood (2009)
Evaluation of Clinical Judgement at Initiation of AML-Therapy in Elderly Patients - A Prospective Randomized Trial.
Authors: Ulrich S. Schuler, Mathias Hanel, Heinrich Bodenstein, Hermann Einsele, Karl-Heinz Pflueger, Norbert Schmitz, Thomas Wagner, Hannes Wandt, Regina Herbst, Ulrich Kaiser, Gerhard Ehninger
Journal: Blood (2007)
Csnk2β, the Regulatory Subunit of Protein Kinase CK2, modulates Peripheral B Cell Development Repressing Notch2 Signaling and Promoting a Proper B-Cell Receptor Signal Transmission
Authors: Fortunato Zaffino, Paolo Macaccaro, Alessandro Casellato, Elisa Mandato, Sabrina Manni, Laura Quotti Tubi, Marco Pizzi, Odile Filhol-Cochet, Brigitte Boldyreff, Gianpietro Semenzato, Francesco Piazza
Journal: Blood (2014)
The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response
Authors: Chiara Tarantelli, Eugenio Gaudio, Ivo Kwee, Andrea Rinaldi, Matteo Stifanelli, Elena Bernasconi, Chiara Barassi, Petra Hillmann, Anastasios Stathis, Laura Carrassa, Massimo Broggini, Georg Stussi, Doriano Fabbro, Paul Hebeisen, Frances Betts, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni
Journal: Blood (2014)
Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.
Authors: Kazunori Murai, Shugo Kowata, Tatsuo Oyake, Tadashi Shimoyama, Maki Asahi, Sugawara Norifumi, Ryosei Sasaki, Suzuki Yuzo, Fujishima Yukiteru, Yasuhiko Tsukushi, Shigeki Ito, Yoji Ishida
Journal: Blood (2012)
Changes in Serum Free Light Chain and Biochemical Markers in Patients with Multiple Myeloma Receiving Bortezomib Treatment.
Authors: Chang-Ki Min, Ki-Seong Eom, Seok Lee, Jong-Wook Lee, Woo-Sung Min, Chong-Won Park, Chun-Choo Kim, Myungshin Kim, Jihyang Lim, Yonggoo Kim, Kyungja Han
Journal: Blood (2006)
Unusual Presentations of Germ Cell Tumors
Authors: Lisa Horvath, David McDowell, Graham Stevens, Richard Parkinson, Stanley McCarthy, Michael Boyer
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.3.911 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11157045 Unusual Presentations of Germ Cell Tumors Case 2. Seminoma of the Conus Medullaris Lisa HorvathxLisa HorvathSearch for articles by this author , David McDowellxDavid McDowellSearch for articles by this author , Graham StevensxGraham StevensSearch for articles by this author , Richard ParkinsonxRichard ParkinsonSearch for articles by this author , Stanley McCarthyxStanley McCarthySearch for articles by this author , Michael BoyerxMichael BoyerSearch for articles by this author Show More Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia https://doi.org/10.1200/JCO.2001.19.3.911 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology